Drug Profile
Enmetazobactam/piperacillin - Allecra Therapeutics
Alternative Names: AAI101/Piperacillin; Piperacillin/AAI101Latest Information Update: 28 Oct 2020
Price :
$50
*
At a glance
- Originator Allecra Therapeutics
- Class Antibacterials; Penicillins; Sulfones
- Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Gram-negative infections
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for phase-I development in Gram-negative-infections in Germany
- 12 Sep 2017 Phase-I clinical trials in Gram-negative infections in Germany (unspecified route) (Allecra Therapeutics pipeline, September 2017)